Suchergebnisse - Markus Perl

From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases von Leonard Knoedler, Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Konstantin Herfeld, Helia Hosseini, Sam Boroumand, Viola A. Stoegner, Viola A. Stoegner, Ali-Farid Safi, Ali-Farid Safi, Markus Perl, Markus Perl, Samuel Knoedler, Samuel Knoedler, Bohdan Pomahac, Martin Kauke-Navarro

Volltext

The Gb3-synthase A4GALT is an epigenetically regulated driver of tumor invasiveness in gastrointestinal cancer von Noah-David Hirsch, Markus Perl, Simon Holzinger, Christoph Barz, Stefan Enßle, Widya Johannes, Anja Conrad, Jonas J. Unterholzner, Viktoria Obermeier, Markus Tschurtschenthaler, Ludger Johannes, Klaus-Peter Janssen

Volltext

Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy von Stefan Enssle, Anna Sax, Peter May, Nadia El Khawanky, Nardine Soliman, Markus Perl, Julius C. Enssle, Karsten Krey, Jürgen Ruland, Andreas Pichlmair, Florian Bassermann, Hendrik Poeck, Simon Heidegger

Volltext

Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies von Markus Perl, Konstantin Herfeld, Dennis C. Harrer, Matthias Höpting, Marina Schweiger, Ulrich Sterz, Leonard Knödler, Susanne Heimerl, Leo Hansmann, Wolfgang Herr, Hendrik Poeck, Daniel Wolff, Matthias Edinger, Christina Hart, Matthias A. Fante

Volltext

CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors—A narrative review von Leonard Knoedler, Konstantin Herfeld, Daniel A. Schaefer, Fortunay Diatta, James Clune, Brogan Evans, Michelle Seu, Bong-Sung Kim, Michael Alfertshofer, Thomas Schaschinger, Jasper Iske, Samuel Knoedler, Alexandre G. Lellouch, Maxime Jeljeli, Alberto Carturan, Marco Ruella, Max Heiland, Hendrik Poeck, Markus Perl, Bohdan Pomahac, Martin Kauke-Navarro

Volltext

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients von Alexander Scheiter, Simon Mellin, Felix Keil, Johannes Meier, Daniel Heudobler, Christina Brummer, Sabine Einhell, Benjamin Zwicker, Elena Wutzlhofer, Frederik Hierl, Sophie Klemm, Elena Lüftl, Tom Schneider, Markus Perl, Margit Klier-Richter, Alexander Immel, Till Kaltofen, Matthias Grube, Elisabeth Bumes, Stephan Seitz, Christian Schulz, Sebastian Haferkamp, Konstantin Drexler, Anja Troeger, Felix Steger, Sophie Schlosser-Hupf, Hauke Christian Tews, Arne Kandulski, Kristina Wohlfart, Ramona Erber, Ines Schönbuchner, Davor Lessel, Marco J. Schnabel, Anja M. Sedlmeier, Monika Klinkhammer-Schalke, Julia Maurer, Diego F. Calvisi, Tobias Pukrop, Ulrich Kaiser, Daniela Hirsch, Wolfgang Dietmaier, Matthias Evert, Florian Lüke, Kirsten Utpatel

Volltext

The microbial metabolite desaminotyrosine protects against graft-versus-host disease via mTORC1 and STING-dependent intestinal regeneration von Sascha Göttert, Erik Thiele Orberg, Kaiji Fan, Paul Heinrich, Diana M. Matthe, Omer Khalid, Lena Klostermeier, Chiara Suriano, Nicholas Strieder, Claudia Gebhard, Eva Vonbrunn, Andreas Mamilos, Daniela Hirsch, Elisabeth Meedt, Karin Kleigrewe, Andreas Hiergeist, Alix Schwarz, Joachim Gläsner, Sakhila Ghimire, Laura Joachim, Florian Voll, Klaus Neuhaus, Klaus-Peter Janssen, Markus Perl, Franziska Pielmeier, Jürgen Ruland, Marina Kreutz, Daniela Weber, Christian Schmidl, Natalie Köhler, Markus Tschurtschenthaler, Petra Hoffmann, Matthias Edinger, Daniel Wolff, Florian Bassermann, Michael Rehli, Dirk Haller, Matthias Evert, Kai Hildner, Maike Büttner-Herold, Wolfgang Herr, André Gessner, Simon Heidegger, Ernst Holler, Hendrik Poeck

Volltext